Gabriela de Boer, MD
Ophthalmology · Hickory, NCNPI 1033471768
Payments from drug & device makers
Across 92 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$430
- Bausch & Lomb Americas Inc.$338
- Thea Pharma Inc.$225
- Alcon$209
- Oyster Point Pharma, Inc.$202
- Omeros Corporation$134
- plus $578 from 15 others
What the payments were for
- Food & beverage$2,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 27 | $430 |
| Bausch & Lomb Americas Inc. | 8 | $338 |
| Thea Pharma Inc. | 14 | $225 |
| Alcon | 8 | $209 |
| Oyster Point Pharma, Inc. | 10 | $202 |
| Omeros Corporation | 3 | $134 |
| Novartis | 4 | $92 |
| Alcon Puerto Rico Inc | 1 | $83 |
| Tarsus Pharmaceuticals, Inc. | 3 | $67 |
| AbbVie | 2 | $59 |
| Lensar, Inc. | 1 | $52 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $22 |
| Ivantis, Inc | 1 | $21 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,117 in reported general payments places this provider in the 55th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 241 | $272,210 |
| XdemvyLotilaner | 82 | $152,590 |
| TyrvayaVarenicline Tartrate | 79 | $51,432 |
| XiidraLifitegrast | 28 | $35,512 |
| LumiganBimatoprost | 52 | $24,349 |
| MieboPerfluorohexyloctane/Pf | 21 | $16,695 |
| Prednisolone Acetate | 615 | $15,930 |
| EysuvisLoteprednol Etabonate | 32 | $15,694 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,041 |
| Restasis MultidoseCyclosporine | 11 | $7,130 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $5,079 |
| Latanoprost | 336 | $2,902 |
| MoxifloxacinMoxifloxacin Hcl | 92 | $2,115 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,938 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 95 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $59 | $308,769325 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $67 | $152,59082 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $338 | $52,20749 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $202 | $51,43279 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $39 | $15,69432 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $22 | $11,04130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Hickory
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Patrick KeltyHickory$1.1M
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Rajiv ShahWinston Salem$1.3M
- Julie WoodwardDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.